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ABSTRACT
We have investigated the role of vascular-endothelial (VE)-cadherin in melanoma 
and breast cancer metastasis. We found that VE-cadherin is expressed in highly 
aggressive melanoma and breast cancer cell lines. Remarkably, inactivation of VE-
cadherin triggered a significant loss of malignant traits (proliferation, adhesion, 
invasion and transendothelial migration) in melanoma and breast cancer cells. These 
effects, except transendothelial migration, were induced by the VE-cadherin RGD 
motifs. Co-immunoprecipitation experiments demonstrated an interaction between 
VE-cadherin and α2β1 integrin, with the RGD motifs found to directly affect β1 
integrin activation. VE-cadherin-mediated integrin signaling occurred through specific 
activation of SRC, ERK and JNK, including AKT in melanoma. Knocking down VE-
cadherin suppressed lung colonization capacity of melanoma or breast cancer cells 
inoculated in mice, while pre-incubation with VE-cadherin RGD peptides promoted lung 
metastasis for both cancer types. Finally, an in silico study revealed the association of 
high VE-cadherin expression with poor survival in a subset of melanoma patients and 
breast cancer patients showing low CD34 expression. These findings support a general 
role for VE-cadherin and other RGD cadherins as critical regulators of lung and liver 
metastasis in multiple solid tumours. These results pave the way for cadherin-specific 
RGD targeted therapies to control disseminated metastasis in multiple cancers.
INTRODUCTION
Metastasis, the final step of malignant 
transformation, is a complex process with numerous 
distinct and sequential steps. Organ-specific metastasis 
depends on different molecules, including growth factors, 
receptors, proteases, chemokines and cellular adhesion 
molecules, such as cadherins and integrins [1, 2]. Recently, 
we described the presence of tripeptide RGD motifs in 
7D cadherins, cadherin-17 (CDH17; also LI-cadherin) 
and cadherin-16, and type II cadherins, such as vascular 
endothelial (VE)-cadherin (CD144), KSP-cadherin 
(CDH6) and cadherin 20 (CDH20) [3]. CDH17 activates 
the α2β1 integrin pathway through specific RGD motifs to 
promote cell adhesion, proliferation and liver colonization 
in colorectal cancer metastasis [3, 4]. A direct interaction 
between CDH17 and α2β1 integrin was demonstrated 
using various methods, such as affinity chromatography, 
soluble binding of cadherin ectodomains and cell adhesion 
to RGD-containing cadherin domains [3]. 
VE-cadherin is a type II cadherin that contains 
RGD motifs within different domains (e.g. 1, 2 or 3) in 
many mammals and birds, but not in rodents or dogs 
(Supplementary Data Figure 1). In primates, the VE-
cadherin sequence displays two RGD motifs in cadherin 
domains 2 and 3 (Supplementary Data Figure 1). VE-
cadherin is mainly expressed in endothelial cells, where it 
plays a central role in vascular integrity and permeability 
and promotes homotypic cell-to-cell adhesion [5]. 
Intracellular association to β- and γ-catenin (plakoglobin) 
promotes binding to the actin cytoskeleton [6]. Mice 
deficient in VE-cadherin, or expressing truncated VE-
cadherin, die in mid-gestation from severe vascular 
defects, involving endothelial apoptosis and disrupted 
survival signalling pathways [7]. VE-cadherin has 
been used as a target to control tumour angiogenesis 
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in vivo [8]. It is also expressed in Ewing sarcoma [9], 
highly aggressive cutaneous melanomas [10] and it is 
involved in vasculogenic mimicry (the ability to form 
novel blood vessel-like structures) in uveal melanomas 
[11]. VE-cadherin is also expressed in a subset of acute 
lymphoblastic leukemia cells, where contributes to cell 
survival [12], and in a subset of cancer stem cells CD133+ 
in osteosarcoma, ovarian cancer and glioblastoma, 
contributing to vasculogenic mimicry by VEGF-
independent tumour cell differentiation [13]. 
VE-cadherin enhances the capacity of mouse 
mammary tumour cells to proliferate and adhere to 
endothelial cells [14, 15]. Its effects on cell proliferation 
have been commonly attributed to β-catenin release from 
the p120-catenin complex and induction of transcription 
of specific genes [16]. In addition, α2β1 integrin-
mediated phosphorylation of VE-cadherin leads to the 
disorganization of the endothelial adherens junctions and 
facilitates transendothelial migration of breast cancer cells. 
This effect was mediated by the binding of α2β1 integrin 
to an unknown counterligand on endothelial cells [17]. 
Still, many aspects regarding signalling effects of VE-
cadherin on the epithelial cancer cells and their effect on 
invasion and proliferation were still obscure. 
Here, we investigated the role of VE-cadherin in 
metastasis progression of melanoma and breast cancers. 
We have identified that VE-cadherin activates α2β1 
integrin through its RGD motifs, thereby using the integrin 
signalling pathway to promote adhesion, invasion and 
proliferation. We provide evidence that the VE-cadherin 
RGD motifs promote in vivo lung metastasis in melanoma 
and breast cancers. Moreover, a high expression of 
VE-cadherin in melanoma and breast cancer patients is 
associated to poor prognosis. 
RESULTS
VE-cadherin expression is associated to metastatic 
melanoma and breast cancer cell lines
We analysed VE-cadherin expression and its role in 
metastasis in a panel of 8 melanoma and 4 breast cancer 
cell lines (Figure 1a). Compared to non-invasive MCF7, 
VE-cadherin overexpression was observed in metastatic 
breast cancer cells (SKBR3, MDA-MB-231 and MDA-
MB-468) and metastatic melanoma cell lines (BLM, 
Figure 1: VE-cadherin is expressed in melanoma and breast cancer cell lines. a. Protein lysates of the indicated melanoma 
and breast cancer cell lines were resolved by SDS-PAGE and subjected to western blot using anti-VE-cadherin. Anti-α-tubulin was used 
to assess total protein content. b. Flow cytometry analysis showing the surface expression of VE-cadherin on the indicated cancer cells. 
Inside each panel, mean fluorescence intensity is indicated. c. VE-cadherin expression was assessed by western blot in cell lysates and 48-h 
conditioned media of the indicated melanoma and breast cancer cell lines.
Oncotarget217www.impactjournals.com/oncotarget
A375, SK-MEL-28 and Mel57) except SK-MEL-103. 
VE-cadherin was absent in Mel-STV melanocytes and 
in the poorly metastatic MeWo cell line. Interestingly, 
breast cancer cells exhibited two forms of VE-cadherin 
while melanoma cells showed only one, probably due to 
cell-specific differences in glycosylation. Flow cytometry 
analysis confirmed a correlation between cell surface 
expression of VE-cadherin and total expression observed 
by western blot (Figure 1b). Secretion of the VE-cadherin 
ectodomain was detected in A375 melanoma cancer 
cells and SKBR3 breast cancer cells (Figure 1c). In any 
case, 75% of the cadherin was found in the cell lysate, 
indicating that VE-cadherin signalling would be mainly 
from the cell surface. For the remaining studies, two 
representative metastatic cell lines for each cancer type 
—BLM and A375 for melanoma and MDA-MB-468 and 
SKBR3 for breast cancer—were used.
RGD peptides in VE-cadherin increase adhesion, 
proliferation and invasion in melanoma and 
breast cancer cells
Next, we investigated whether VE-cadherin 
silencing affects the pro-metastatic properties of melanoma 
and breast cancer cells. Cancer cells transfected with 
either one of two distinct VE-cadherin siRNAs exhibited 
a clear reduction of VE-cadherin expression by western 
blot and flow cytometry (Figure 2a and Supplementary 
Data Figure 2a). VE-cadherin silencing led to a significant 
decline in the cellular responses of proliferation, invasion, 
transendothelial migration and adhesion (Figure 2b and 
Supplementary Data Figure 2b). Flow cytometry analysis 
using a monoclonal antibody specific for the high-
affinity conformation of β1 integrin demonstrated that 
VE-cadherin silencing in the four cell lines significantly 
reduced the high affinity conformation (Figure 2c and 
Supplementary Data Figure 2c), but had no effect on 
the total level of β1 integrin expression (Supplementary 
Data Figure 3), indicating that VE-cadherin regulates the 
affinity but not the expression of β1 integrin. We thus 
investigated whether these effects are mediated through 
the VE-cadherin RGD motifs. 
Addition of VE-cadherin RGD peptides significantly 
increased the activation of β1 integrin (Figure 2d), as well 
as the adhesion, invasion and proliferation responses 
in melanoma and breast cancer cells (Figure 2e). With 
respect to the adhesion response, VE-cadherin increased 
cell binding to collagen type I and Matrigel (Figure 
2e). In contrast, the RGD peptides did not affect the 
transendothelial migration capacity of tumour cells 
across an HUVEC endothelial cell monolayer, perhaps 
because the abundant expression of VE-cadherin in 
HUVEC tampers the peptide effects, or perhaps because 
the RGD motif does not participate in homotypic cell-
to-cell interactions [3]. Collectively, these data indicate 
that the VE-cadherin RGD motifs play a major role in 
cell adhesion, invasion and proliferation in melanoma 
and breast cancer cells, which correlate directly with 
β1 integrin activation. The effect of VE-cadherin on 
transendothelial migration is likely mediated by homotypic 
interactions. 
VE-cadherin protein complexes are linked to 
integrin signalling and cell adhesion
In contrast to CDH17, VE-cadherin contains a 
large cytoplasmic domain engaged in signal transmission. 
To characterize the protein-interaction network of 
VE-cadherin, we used immunoprecipitation and mass 
spectrometry. After bioinformatic analysis, we identified 
79 proteins that co-immunoprecipitated specifically with 
VE-cadherin in BLM melanoma cells, and 24 proteins in 
MDA-MB-468 breast cancer cells (Supplementary Data 
Figure 4a and Table 2). The VE-cadherin interaction 
network in both cell types contained α2β1 integrin, αV 
integrin and other proteins mainly involved in cell-matrix 
adhesion, cell-cell adhesion, cell signalling and the actin 
cytoskeleton (Figure 3a and Supplementary Data Figure 
4b). On the other hand, we confirmed the interaction of 
VE-cadherin with p120-catenin and plakoglobin through 
the cytoplasmic domain [16]. In BLM melanoma cells, 
additional interactions with ALCAM, associated with 
high invasiveness and aggressiveness in melanomas, 
were also observed [18]. Among other VE-cadherin-
associated proteins involved in cell signalling, survival 
and proliferation, we identified FAK, SRC, Ras, AXL, 
EPHA2, AKT, STAT1, STAT3, JNK and ERK kinases 
(Figure 3a). Although the number of interacting proteins 
was larger in melanomas than in breast cancer cells, 
many identified proteins were similar and functionally 
equivalent in both cancer types. Therefore, VE-cadherin 
has homologous protein networks in melanoma and breast 
cancer. Interaction between VE-cadherin and integrin may 
occur in trans (Figure 3a) and/or cis (Supplementary Data 
Figure 4c), as experimental data are compatible with both 
options. VE-cadherin-associated proteins were confirmed 
by western blot in the four cell lines, with only a few 
exceptions (lack of Ras in A375 and SKBR3 cells) (Figure 
3b).
The association of VE-cadherin with α2β1 integrin, 
and the presence of αV integrin in the complex, were 
confirmed by combined co-immunoprecipitation and 
silencing studies (Figure 3c, 3d). α2β1 integrin interacts 
with VE-cadherin, as α2 integrin silencing caused the loss 
of VE-cadherin in the immunoprecipitate (Figure 3d and 
Supplementary Data Figure 5). In contrast, αV silencing 
did not change the levels of VE-cadherin. Still, we cannot 
exclude that αV associates with β1, or other integrin β 
subunits, and clusters together with the α2β1 integrin. 
To investigate any potential effects of αVβ1 integrin, we 
carried out αV and α2 integrin silencing in combination 
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Figure 2: VE-cadherin RGD motifs promote cell adhesion, invasion and proliferation. a. BLM and MDA-MB-468 cells 
were transfected with one of two distinct siRNAs against VE-cadherin or with a control siRNA. VE-cadherin expression was assessed by 
western blot and flow cytometry. b. Transfectants were subjected to adhesion onto Matrigel or type I collagen, invasion through Matrigel, 
endothelial transmigration and MTT assays to determinate cell proliferation. Cell adhesion, invasion, transmigration or proliferation was 
significantly inhibited by VE-cadherin knock-down (** P < 0.01, *** P < 0.001). c. Transfectants were analysed by flow cytometry to 
determine the expression of high-affinity β1 integrin conformation. d. BLM and MDA-MB-468 cells were exposed to 9-mer peptides 
containing the RGD motifs and flanking sequences from VE-cadherin domain 2 or domain 3 (CDH5D2 or CDH5D3, respectively) and 
subjected to flow cytometry assays to assess the amount of β1 integrin in high affinity conformation. β1 integrin was significantly activated 
by exposition to the peptides (*** P < 0.001). e. Same as b. but in the presence of the CDH5D2 or CDH5D3 peptide. Cell adhesion, 
invasion or proliferation was significantly enhanced by peptide addition (** P < 0.01, *** P < 0.001).
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Figure 3: Protein networks identified by proteomic analyses after VE-cadherin immunoprecipitation. a. Cell lysates 
from BLM and MDA-MB-468 cells were immunoprecipitated using anti-VE-cadherin or control antibodies. Immunoprecipitates were 
resolved by SDS-PAGE, divided in three fractions and digested with trypsin. The resulting peptides were analysed by nanoLC-MS/MS. The 
diagram displays the proteins that were determined to specifically bind to VE-cadherin by bioinformatic analyses and data mining. b. Cell 
lysates from the indicated cells lines were immunoprecipitated as before, resolved by SDS-PAGE and analyzed by western blot using the 
indicated antibodies. c. Analysis by western blot of cell lysates from BLM and MDA-MB-468 immunoprecipitated using anti-VE-cadherin, 
anti-α2 integrin, anti-αv integrin or control antibodies. d. BLM or MDA-MB-468 cells were transfected with siRNAs against α2 integrin, 
αv integrin or control siRNAs. Cell lysates from the transfectants were subjected to immunoprecipitation using the indicated antibodies and 
analyzed by western blot. e. The same siRNA transfectants were exposed to the indicated peptides. β1 integrin was significant activated by 
exposition to the peptides (** P < 0.01).
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with RGD peptide stimulation in BLM melanoma and 
MDA-MB-468 breast cancer cell lines (Figure 3e). 
Activation of β1 integrin by RGD peptides was blocked 
by α2 integrin silencing but not by αV silencing in both 
cell lines (Figure 3e). As expected, mutant RAD peptides 
failed to activate β1 integrin. In summary, the VE-cadherin 
interacting network consisted of α2β1 integrin and a large 
number of proteins from the integrin signalling pathway, 
actin cytoskeleton and cell adhesion, in addition to p120 
catenin and plakoglobin. 
VE-cadherin signalling is involved in cell 
proliferation, invasion and endothelial 
transmigration in melanoma and breast cancer 
cells
We next investigated downstream mediators 
of VE-cadherin-α2β1 integrin signalling pathway in 
melanoma and breast cancer cells using specific inhibitors. 
Integrin signalling mediates different aspects of cancer 
progression, including invasion and proliferation [19]. 
After VE-cadherin silencing, phosphorylation of SRC, 
ERK and JNK was significantly decreased in both 
cell lines, and that of AKT in BLM melanoma cells 
(Figure 4a). Whereas enhanced integrin signalling was 
observed after incubation with the RGD peptides, no 
changes in phosphorylation were observed after using 
the respective RAD mutant sequences (Figure 4a). We 
then tested specific inhibitors for SRC, FAK, AKT, ERK/
MEK and JNK to examine their effects on the metastatic 
properties, using either VE-cadherin-silenced or mock-
silenced cells. None of these inhibitors affected β1 
integrin activation or cell adhesion (Supplementary Data 
Figure 6). However, significant effects were observed for 
invasion, transendothelial migration and proliferation 
(Figure 4b). SRC (PP2), AKT and ERK/MEK (UO126) 
inhibitors provoked a clear decrease in the invasive 
and transendothelial migration capacity of scrambled 
melanoma and breast cancer transfectants, similar to 
those achieved by VE-cadherin-silenced counterparts. No 
effects were observed with the FAK or the JNK inhibitors 
in invasion or transendothelial migration. In contrast, AKT 
activation in breast cancer cells was important in both, 
invasion and transmigration, by mechanisms VE-cadherin-
independent (Figure 4a). A decrease in proliferation was 
observed after using PP2, UO126 and JNK inhibitors in 
both cancer types. Proliferation of BLM melanoma cell 
was also sensitive to the FAK inhibitor in a mechanism 
VE-cadherin-independent (Figure 4a). Inhibitors did 
not affect significantly to VE-cadherin-silenced cell 
proliferation. Collectively, these results indicate that VE-
cadherin promotes invasion and transendothelial migration 
by activation of the α2β1 integrin pathway through SRC 
and ERK. JNK activation was also implicated in cell 
proliferation. 
VE-cadherin promotes metastatic colonization in 
lung through its RGD motifs
We next investigated the role of VE-cadherin and 
its RGD motifs in melanoma and breast cancer metastasis 
in vivo. We hypothesized that pre-incubation of the 
cells with the peptides should activate α2β1 integrin 
and, consequently, the pro-metastatic activity of the 
cells. For this study, we intravenously inoculated VE-
cadherin knockdown or wild-type control cells in mice 
and investigated whether lung metastasis was induced by 
testing for the presence of human GAPDH in lung tissue. 
Mice were tested at 96 h post-inoculation to avoid non-
specific cell binding to the lung. Lungs obtained from 
mice inoculated with VE-cadherin-silenced cells showed 
a much lower amount of the human housekeeping GAPDH 
gene than those inoculated with control cells (Figure 5a). 
In addition, lung metastasis after 5 weeks was significantly 
decreased in mice inoculated with VE-cadherin silenced 
BLM melanoma cells, compared to mice inoculated with 
control siRNA transfectants (Figure 5b). To confirm the 
pro-metastatic role of the VE-cadherin RGD motifs, we 
pre-incubated the cells with 9-mer peptides containing 
the RGD motifs in domains 2 and 3 prior to mouse 
inoculation. After 96 h, we noticed a significant increase 
in the lung colonization of melanoma and breast cancer 
cells, especially after using domain 3 RGD (Figure 5c). 
This increase in metastatic colonization was lost when 
the RGD peptides were replaced by the inactive RAD 
mutant peptides (Figure 5c). Altogether, these experiments 
revealed an important role of VE-cadherin with 
involvement of the RGD motifs in the lung metastasis of 
melanoma and breast cancer cells. 
Impact of VE-cadherin expression in patient 
survival
Little is known about the impact of VE-cadherin 
expression on the clinical outcome of melanoma and breast 
cancer patients. To explore the prognostic and clinical 
value of VE-cadherin in patients, we performed in silico 
analysis of overall survival using GEO datasets. As VE-
cadherin is also expressed by endothelial cells, which are 
usually found in the tumours, we tested only samples with 
low expression of CD34, a marker of endothelial cells, to 
discard tumours with an excessive angiogenesis that might 
lead to confusing results. In melanoma and breast cancer, 
CD34 low patients with high expression of VE-cadherin 
exhibited a significant reduction in their survival time 
(log-rank P = 0.049, log-rank P = 0.019, respectively) 
(Figure 5d). Thus, high VE-cadherin expression was 
associated in a statistically significant manner with poorer 
overall survival for melanoma and breast cancer patients. 
In contrast, we did not find association between CD34 
expression and survival (Figure 5e). These results support 
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Figure 4: VE-cadherin regulates the activation of signalling proteins involved in cell invasion, transmigration and 
proliferation. Cancer cells were transfected with a. VE-cadherin or control siRNAs or b. exposed to the indicated peptides. Cell lysates 
were analyzed by western blot using the indicated antibodies. Bands were quantified using MultiGauge software. b. siRNA transfectants 
were tested in cell invasion, endothelial transmigration and MTT assays in presence of the indicated chemical inhibitors.
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that the correlation between VE-cadherin expression and 
overall survival in melanoma and breast cancer patients is 
not due to high vascularization of the tumours.
DISCUSSION
Here, we have demonstrated that VE-cadherin 
plays a major role in the induction of pro-metastatic 
properties—adhesion, invasion and proliferation—in 
different melanoma and breast cancer cell lines. We 
provide different pieces of evidence that the functional 
effects were mediated by binding of the VE-cadherin 
RGD motifs to α2β1 integrin. A model of the signalling 
pathway is represented in Figure 6. These results confirm 
the relevance of RGD cadherins in the development of 
cancer metastasis in multiple tumours. 
However, beyond cell specificity, there are 
important differences between RGD cadherins from a 
mechanistic point of view. For instance, VE-cadherin has 
two RGD motifs, which are located in domains 2 and 3 
and are far from the cell surface, while CDH17 has one 
RGD, which is located in domain 7 and is quite close 
to the cell membrane. Moreover, while VE-cadherin 
contains a functional cytoplasmic domain [16], CDH17 
contains a very small cytoplasmic domain not adequate 
for intracellular signalling. CDH17-mediated integrin 
activation was observed to mainly affect adhesion and 
proliferation in colorectal cancer [4], while VE-cadherin 
RGD motifs also affected invasion in melanoma and breast 
cancer cells. Whereas metastatic colorectal cancer cells 
lose their capacity to bind collagen type I and preferably 
bind collagen IV after CDH17 activation of α2β1 integrin 
[3], melanoma and breast cancer cells retained their 
Figure 5: VE-cadherin expression is associated with lung metastasis in mouse models and poor survival in melanoma 
and breast cancer patients. a. BLM, A375, MDA-MB-468 or SKBR3 cells transfected with VE-cadherin or control siRNAs were 
inoculated intravenously in nude mice. After 4 days, mice were euthanized and lung mRNAs were isolated and subjected to RT-PCR 
to amplify human GAPDH. As a control, mouse β-actin was also amplified. b. BLM cells transfected with the indicated siRNAs were 
inoculated intravenously in nude mice (n = 4). After 35 days, mice were euthanized and macroscopic lung metastases were measured. c. 
Cancer cells were inoculated in nude mice together with a peptide containing the RGD motifs (CDH5D2 or CDH5D3) or an irrelevant RAD 
sequence (CDH5D2RAD or CDH5D3RAD), as indicated. After 4 days, lung mRNAs were isolated and analysed by RT-PCR as before. d. 
Significant association of VE-cadherin expression with shorter survival of melanoma and breast cancer patients was found using the log-
rank test. e. CD34 expression is not associated with poor survival in melanoma and breast cancer patients as found using the log-rank test.
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binding capacity to collagen I. These differences in 
collagen-binding capacities between both cadherins are 
probably due to the fact that liver parenchyma is mainly 
composed of collagen type IV, while lung parenchyma 
mostly contains type I and III collagen [20]. This is, they 
are related to the organ-specificity in the final metastatic 
colonization. In vivo experiments showed that VE-
cadherin silencing decreases lung colonization, while 
the addition of VE-cadherin RGD peptides potentiate the 
metastatic colonization of the lung. 
It is interesting that many animal models used 
in cancer research, such as rodents or dogs, lack RGD 
motifs in their VE-cadherin sequence (Supplementary 
Data Figure 1). In contrast, the VE-cadherin sequence in 
most primates contains two RGD domains, implicating 
a relatively late trait acquisition that might provide 
some evolutionary advantage. Metastatic cells might 
take advantage of this evolutionary trait to improve 
their proliferation and invasion capacity. The lack of 
RGD motifs in rodent cadherins highlights that caution 
should be used with direct extrapolations of mouse cancer 
metastasis models to humans, but it also implies the 
existence of additional ways for metastatic colonization. 
Our experiments indicate that VE-cadherin 
signalling does not involve αVβ1 integrin, which has been 
considered to be an RGD receptor [21], nor αVβ3, which 
was not detected. In any case, the presence of αV in the 
complex deserves further investigation. In addition, we 
observed an interaction of VE-cadherin with p120-catenin 
and plakoglobin, but not with β-catenin. Therefore, VE-
cadherin in cancer cells keeps its cytoskeleton binding 
capacity (actin-binding) but does not seem to require the 
interaction with β-catenin for SRC or FAK activation, 
as it does in endothelial cells [16]. In cancer cells, SRC, 
ERK and JNK activation would mediate the VE-cadherin/
integrin signalling. VE-cadherin effects on proliferation of 
metastatic mammary cancer cells, which were previously 
attributed to the TGFβ pathway [14], could also be 
explained with the outside-in α2β1 integrin activation 
and the subsequent activation of the SRC, ERK and JNK 
pathways. Still, we cannot rule out that VE-cadherin 
might promote TGFβ activation through other indirect 
interactions. A correlation between higher expression of 
α2β1 integrin and higher invasiveness was previously 
observed in breast cancer cells [17]. RGD binding might 
additionally promote tyrosine phosphorylation of VE-
cadherin in endothelial cells, which is mediated by α2β1 
integrin in invasive breast cancer cells [17]. In addition, 
tyrosine phosphorylation of VE-cadherin initiates the 
β-catenin dissociation from the p120-catenin complex to 
disrupt the endothelial barrier [22]. Since VE-cadherin 
is phosphorylated in cancer cells, it might explain why 
β-catenin was absent from our interaction data. 
VE-cadherin is expressed also in endothelial cells 
and the in silico meta-analysis was carried out using RNA 
expression data from complete tumour tissues, which 
Figure 6: VE-cadherin promotes metastatic colonization. VE-cadherin RGD motifs might interact with α2β1 integrin either 
inter- or intracellularly, thereby increasing its affinity for ligands in the extracellular matrix and leading to an increase of cell adhesion 
and signalling activation proteins. Integrin activation increases the ability of cancer cells to invade and proliferate, and consequently their 
metastatic capacity.
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contain not only epithelial cells but stromal and endothelial 
cells. Therefore, more VE-cadherin could correlate with 
more angiogenesis, which in turn could finally affect the 
patient’s survival. To clarify this point and to avoid a 
misinterpretation, we classified the tumours according to 
the expression of the endothelial marker CD34 in order to 
discard those tumours with high angiogenesis and vessels 
content from the analysis. While no association of CD34 
expression with survival was observed, those melanoma 
and breast cancer patients who expressed high levels of 
VE-cadherin and low levels of CD34 showed a clear 
association with worst prognosis. 
In summary, these studies confirm the key role of 
VE-cadherin and their RGD motifs in facilitating integrin 
activation and metastatic colonization in multiple cancer 
types. Interestingly, RGD motif was not required for 
homotypic interaction or transendothelial migration. The 
dissociation of the homotypic cell-cell interaction from 
the RGD-integrin signalling might avoid interfering with 
vascular stability. The enhancement of melanoma and 
breast cancer lung metastasis by the VE-cadherin RGD 
motif highlights the value of cadherin-specific RGD 
targeting as a novel therapeutic strategy for multiple 
types of cancer and metastasis. This strategy might be 
especially relevant for aggressive melanomas (including 
uveal melanoma) and breast cancer subtypes with poor 
prognoses, which are particularly resistant to current 
therapies. 
MATERIALS AND METHODS
Cell lines, culture and reagents
Cells were cultured in Dulbecco´s modified Eagle 
medium (DMEM) (Invitrogen) or RPMI (MeWo cells) 
containing 10% foetal calf serum (Invitrogen) and 
antibiotics at 37ºC in a 5% CO
2
-humidified atmosphere. 
Mel57 and SK-MEL-103 were gifts from Dr M. Soengas, 
MeWo and SK-MEL-28, from Dr P. Real (CNIO, Madrid, 
Spain), BLM cells, from Dr G. van Muijen (University 
Hospital, Nijmegen, The Netherlands), Mel-STV, from 
Dr. R. Weinberg (MIT, Cambridge, MA, USA) and MDA-
MB-468 and SKBR3, from Drs A Aranda and A Villalón, 
respectively (IIBB, Madrid, Spain). Cell lines A375, 
MDA-MB-231, MCF7 and RKO cells were purchased 
from the ATCC and passaged fewer than 6 months after 
purchase for all the experiments.
The following siRNAs were used for expression 
silencing: VE-cadherin, SASI-Hs01_00100751 or 
EHU131141 (Sigma) (assays were carried out with each 
one of the two siRNAs, with consistently equivalent 
results), integrin αV, SASI_Hs01_00220507 (Sigma), 
and integrin α2, SASI_Hs01_00123982 (Sigma). These 
siRNAs were transfected in tumour cells using JetPrime 
reagent (PolyPlus). In each transfection, an aliquot of cells 
was lysed and analyzed by western blot to assess VE-
cadherin expression silencing. Antibodies used are listed 
in the Supplementary Data Table S2. Nine-amino-acid 
peptides containing the RGD motifs from VE-cadherin 
were chemically synthesized in a Focus XC peptide 
synthesizer (AAPPTec, KY, USA). The peptides, named 
according to the cadherin domain where the RGD motif 
is found, were CDH5D2 (QGLRGDSGT, residues 233-
241) and CDH5D3 (SILRGDYQD, residues 296-304). As 
a negative control, peptides with the RGD motif mutated 
into an irrelevant RAD sequence—CDH5D2RAD or 
CDH5D3RAD—were used. The following inhibitors were 
used: UO126 and AKT inhibitor V (Calbiochem), PP2 
(Sigma-Aldrich), JNK inhibitor II (Merck Chemicals) and 
the FAK inhibitor 14 (Santa Cruz Biotechnology).
Flow cytometry
Cells were detached in PBS with 2 mM EDTA, 
washed and resuspended in PBS with human gamma 
globulin (10 μg ml-1) in presence of primary antibodies 
(10 μg ml-1) and incubated for 40 min. After washing, 
cells were incubated in the same medium with Alexa 
468-labelled anti-mouse IgG antibodies (DAKO A/S) 
for 30 min. Data were analysed in a Coulter Epics XL 
cytofluorometer.
Cell adhesion and proliferation
Cell adhesion and proliferation assays were carried 
out as previously described [3].
Cell invasion assays
For invasion, 3 × 104 cells were resuspended in 
serum-free DMEM and loaded onto 8-μm pore-size 
filters coated with 35 μL of a 1:3 dilution of Matrigel 
on Transwells (Costar). The lower compartments of 
the invasion chambers were filled with DMEM with 
5% serum, while inhibitors were added to the upper 
compartments. After 40 h of incubation at 37°C, non-
invading cells were removed from the upper surface 
of the filter, and invasive cells were fixed with 4% 
paraformaldehyde (Sigma-Aldrich), stained with crystal 
violet and counted under a microscope.
Transendothelial migration assays
HUVEC cells (5 × 104) were plated on 8-μm pore-
size filter coated with fibronectin (20 μg ml-1; Invitrogen), 
and confluent monolayers were incubated 16 h before the 
assay with TNF-β (15 ng ml-1, R&D Systems). Tumour 
cells (3 × 104) were resuspended in serum-free DMEM, 
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loaded onto the filters and incubated 24 h. After non-
migrating cells and endothelial cells had been removed, 
migrating cells were fixed, stained and counted as for 
invasion assays.
Western blot and immunoprecipitation
Cells were detached, washed and lysed with 
proteases and phosphatase inhibitors in lysis buffer (1% 
Igepal, 100 mM NaCl, 2 mM MgCl
2
, 10% glycerol, 50 
mM Tris-HCl). Conditioned media were concentrated 
10 times using Vivaspin 15R (Sartorius). Protein 
extracts were separated in SDS-PAGE and transferred 
to nitrocellulose membranes, which were incubated 
with primary antibodies followed by incubation with an 
HRP-coupled secondary antibody (Thermo Scientific) 
and with SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific). Densitometry analysis 
was performed with Quantity One software (Bio-Rad). 
For immunoprecipitation, cells were lysed as before, and 
500 μg of lysate were incubated with 100 µL of protein G 
sepharose to avoid unspecific protein binding, followed 
by incubation with the indicated antibodies and protein G 
sepharose beads (Sigma-Aldrich). After washing, samples 
were boiled and loaded on SDS-PAGE gels for western 
blot analysis and mass spectrometry. 
Mass spectrometry of immunoprecipitated 
proteins
For proteomic analysis, 10 mg of cell lysates were 
immunoprecipitated and the proteins were separated by 
SDS-PAGE, which were then divided in three slices for 
in-gel digestion with trypsin. Proteins were identified by 
mass spectrometry as previously described [4]. Identified 
peptides were validated using Percolator algorithm with a 
q-value threshold of 0.01. Identified proteins were filtered 
by using the CRAPome tool to discard contaminant 
proteins [23]. 
In vivo animal experiments
For lung metastasis, 1 × 106 BLM, A375, SKBR3 
or MDA-MD-468 cells in 0.1 ml PBS were injected in 
the tail vein of Swiss nude mice (Charles River). Short 
term colonization assays were performed as described 
previously [24]. In brief, mice were euthanized 4 days 
after inoculation, and RNA was isolated from lungs using 
TRIzol Reagent (Invitrogen) and retrotranscribed. The 
cDNA was subjected to 30 cycles of PCR with TaqDNA 
polymerase (Invitrogen) to amplify human GAPDH, a 
housekeeping gene. For siRNA-transfected cancer cells, 
1 μL of the previous reaction was subjected to additional 
25-cycle amplification. As a loading control, a 30-cycle 
amplification of murine β-actin was performed. For 
long term assays, mice were euthanized 5 weeks after 
inoculation, and macroscopic lung metastases were 
counted and measured.
In silico prognostic studies
Independent external cohorts of patients were used 
for the prognostic study. The GSE65904 database, which 
contains a cohort of 214 frozen melanoma samples and 
the GSE7390 and GSE45255 databases with 198 and 
139 breast cancer samples, respectively, were used. Data 
were normalized using cubic spline method (melanoma) 
or MAS5 bioconductor (breast cancer), downloaded, and 
z-score ratios were obtained by subtracting the average 
z-score for the cohort from each individual z-score 
and dividing the result by the standard deviation of the 
z-scores for the cohort, in order to remove technical 
variations between datasets. CD34, an endothelial marker, 
and VE-cadherin were independently assessed for each 
database. Negative and positive z-score were considered 
as low and high expression, respectively. Only samples 
with low CD34 expression were analysed for VE-cadherin 
expression to avoid those samples with more endothelial 
cells/angiogenesis. The prognostic value of VE-cadherin 
was assessed using Kaplan-Meier survival curves, which 
were plotted using IBM SPSS Statistics 2.0. Log-rank test 
P value was determined for differences in overall survival. 
Statistical analyses
Data were analysed by Student’s t test (2 conditions) 
or by one-way ANOVA followed by Tukey-Kramer 
multiple comparison test (more than 2 conditions). 
Survival curves were plotted with Kaplan-Meier technique 
and compared with the log-rank test. The minimum 
acceptable level of significance was P < 0.05.
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